<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article" xml:lang="EN"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">PPAR Res</journal-id><journal-id journal-id-type="publisher-id">PPAR</journal-id><journal-title>PPAR Research</journal-title><issn pub-type="ppub">1687-4757</issn><issn pub-type="epub">1687-4765</issn><publisher><publisher-name>Hindawi Publishing Corporation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">19197377</article-id><article-id pub-id-type="pmc">2633453</article-id><article-id pub-id-type="doi">10.1155/2008/286249</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>The Role of NF-<italic>&#x003ba;</italic>B in PPAR<italic>&#x003b1;</italic>-Mediated Hepatocarcinogenesis</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Glauert</surname><given-names>Howard P.</given-names></name><xref ref-type="aff" rid="I1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1">*</xref></contrib><contrib contrib-type="author"><name><surname>Calfee-Mason</surname><given-names>Karen</given-names></name><xref ref-type="aff" rid="I2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Yixin</given-names></name><xref ref-type="aff" rid="I3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Nilakantan</surname><given-names>Vani</given-names></name><xref ref-type="aff" rid="I4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Twaroski</surname><given-names>Michelle L.</given-names></name><xref ref-type="aff" rid="I5"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>Tharappel</surname><given-names>Job</given-names></name><xref ref-type="aff" rid="I1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Spear</surname><given-names>Brett T.</given-names></name><xref ref-type="aff" rid="I6"><sup>6</sup></xref></contrib></contrib-group><aff id="I1"><sup>1</sup>Graduate Center for Nutritional Sciences, University of Kentucky, Lexington, KY 40536, USA</aff><aff id="I2"><sup>2</sup>College of Health and Human Services, Western Kentucky University, Bowling Green, KY 42101, USA</aff><aff id="I3"><sup>3</sup>Applied Biosystems, Foster City, CA 94404, USA</aff><aff id="I4"><sup>4</sup>Division of Transplant Surgery, Kidney Disease Center, Medical College of Wisconsin, Milwaukee, WI 53226, USA</aff><aff id="I5"><sup>5</sup>Food and Drug Administration, CFSAN/OFAS/DFCN, College Park, MD 20740, USA</aff><aff id="I6"><sup>6</sup>Department of Microbiology, Immunology, and Molecular Genetics, University of Kentucky, Lexington, KY 40536, USA</aff><author-notes><corresp id="cor1">*Howard P. Glauert: <email>hglauert@uky.edu</email></corresp><fn fn-type="other"><p>Recommended by Dipak Panigrahy</p></fn></author-notes><pub-date pub-type="ppub"><year>2008</year></pub-date><pub-date pub-type="epub"><day>29</day><month>1</month><year>2009</year></pub-date><volume>2008</volume><elocation-id>286249</elocation-id><history><date date-type="received"><day>30</day><month>5</month><year>2008</year></date><date date-type="rev-recd"><day>3</day><month>10</month><year>2008</year></date><date date-type="accepted"><day>3</day><month>11</month><year>2008</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2008 Howard P. Glauert et al.</copyright-statement><copyright-year>2008</copyright-year><license license-type="open-access"><p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p></license></permissions><abstract><p>In this review, the role of NF-<italic>&#x003ba;</italic>B in the induction of hepatocarcinogenesis by peroxisome proliferators is examined. The administration of peroxisome proliferators for more than a three-day period leads to the activation of NF-<italic>&#x003ba;</italic>B in the livers of rats and mice. On the other hand, peroxisome proliferator activated receptor-<italic>&#x003b1;</italic> (PPAR<italic>&#x003b1;</italic>) activation in non-hepatic tissues can lead to the inhibition of NF-<italic>&#x003ba;</italic>B activation. Several lines of evidence support the hypothesis that the activation of NF-<italic>&#x003ba;</italic>B by peroxisome proliferators in the liver is mediated by oxidative stress. The role of NF-<italic>&#x003ba;</italic>B in peroxisome proliferator-induced hepatocarcinogenesis has been examined using NF-<italic>&#x003ba;</italic>B knockout models. Specifically, the induction of cell proliferation and the promotion of liver carcinogenesis are inhibited in mice lacking the p50 subunit of NF-<italic>&#x003ba;</italic>B. Overall, the activation of NF-<italic>&#x003ba;</italic>B appears to be important in the carcinogenic activity of peroxisome proliferators.</p></abstract></article-meta></front><body><sec sec-type="section" id="sec1"><title>1. INTRODUCTION</title><p>Peroxisome proliferators (also known as PPAR<italic>&#x003b1;</italic>agonists) are a group of chemically distinct compounds capable of elicitingpersistent peroxisome proliferation in hepatocytes and inducing liver tumors inrats and mice [<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B2">2</xref>]. These chemicals activate theperoxisome proliferator-activated receptor <italic>&#x003b1;</italic> (PPAR<italic>&#x003b1;</italic>)which is essential for the carcinogenic properties of these agents [<xref ref-type="bibr" rid="B3">3</xref>]. The administration ofperoxisome proliferators increases the size and number of peroxisomes and activatesgenes encoding several enzymes of the peroxisomal <italic>&#x003b2;</italic>-oxidation pathway [<xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B5">5</xref>]. The rate-limiting enzyme ofthis pathway, fatty acyl CoA oxidase (FAO), produces hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>)as a by-product. In addition, the induction of cytochrome P450 4A enzymes by peroxisome proliferators, which is mediated through PPAR<italic>&#x003b1;</italic>, produces superoxide anions as by-products [<xref ref-type="bibr" rid="B6">6</xref>]. Oxidative stress may beimportant in the toxicity and carcinogenicity of peroxisome proliferators, viathe induction of lipid peroxidation, oxidative DNA damage, and/or changes ingene expression [<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B7">7</xref>]. The changes in geneexpression may be brought about in part by the activation of the transcriptionfactor NF-<italic>&#x003ba;</italic>B,which is known to be induced by oxidative stress. In this review, we willdiscuss the evidence that peroxisome proliferators activate NF-<italic>&#x003ba;</italic>B, whether NF-<italic>&#x003ba;</italic>B activation is necessary for the induction ofcarcinogenesis by peroxisome proliferators, and the mechanisms by whichperoxisome proliferators may influence NF-<italic>&#x003ba;</italic>B activation.</p></sec><sec sec-type="section" id="sec2"><title>2. NF-<italic>&#x003ba;</italic>B</title><p>Nuclear factor-<italic>&#x003ba;</italic>B (NF-<italic>&#x003ba;</italic>B) is a eukaryotic transcription factor family consisting of the followingproteins: p50 (NF-<italic>&#x003ba;</italic>B1), p65 (RelA), p52 (NF-<italic>&#x003ba;</italic>B2),c-Rel, and RelB. It is normally found in the cytoplasm as an inactive dimer,with the most common being the p50&#x02013;p65 heterodimer, bound to an inhibitorysubunit, I<italic>&#x003ba;</italic>B, which also has several family members, including I<italic>&#x003ba;</italic>B<italic>&#x003b1;</italic>,I<italic>&#x003ba;</italic>B<italic>&#x003b2;</italic>, I<italic>&#x003ba;</italic>B<italic>&#x003b3;</italic>, and I<italic>&#x003ba;</italic>B<italic>&#x003b5;</italic> [<xref ref-type="bibr" rid="B8">8</xref>]. Upon activation, NF-<italic>&#x003ba;</italic>Bis released from I<italic>&#x003ba;</italic>B and translocates to the nucleus, where it binds target sequences of responsivegenes. This process requires the phosphorylation of I<italic>&#x003ba;</italic>B, followed by its subsequent degradation via theubiquitin-mediated 26S proteosome pathway [<xref ref-type="bibr" rid="B8">8</xref>]. A 900 kDa complex, termedthe I<italic>&#x003ba;</italic>B kinase (IKK) complex, has been identified and it consists of two kinasesubunits, IKK<italic>&#x003b1;</italic> and IKK<italic>&#x003b2;</italic>, and a regulatory subunit, IKK<italic>&#x003b3;</italic> [<xref ref-type="bibr" rid="B9">9</xref>, <xref ref-type="bibr" rid="B10">10</xref>]. These two kinase subunitsform homo- or heterodimers that phosphorylate I<italic>&#x003ba;</italic>B molecules, leading to their degradation. Thisactivation pathway for the p50&#x02013;p65 heterodimer has been referred to as theclassical or canonical NF-<italic>&#x003ba;</italic>B signaling pathway, and is dependent on the IKK<italic>&#x003b2;</italic>and IKK<italic>&#x003b3;</italic> subunits of IKK [<xref ref-type="bibr" rid="B11">11</xref>]. An alternative NF-<italic>&#x003ba;</italic>Bsignaling pathway has also been identified, in which IKK<italic>&#x003b1;</italic>is required and it results in the activation of the p52-RelB heterodimer [<xref ref-type="bibr" rid="B11">11</xref>].</p><p>One of the many mechanisms by which NF-<italic>&#x003ba;</italic>Bcan be activated is by increased oxidative stress. NF-<italic>&#x003ba;</italic>B can be activated in vitro by H<sub>2</sub>O<sub>2</sub>, and its activation canbe inhibited by antioxidants, such as vitamin E or N-acetyl cysteine (NAC), orby increased expression of antioxidant enzymes [<xref ref-type="bibr" rid="B12">12</xref>&#x02013;<xref ref-type="bibr" rid="B18">18</xref>]. In addition, agents that activate NF-<italic>&#x003ba;</italic>Bfrequently also increase oxidative stress [<xref ref-type="bibr" rid="B19">19</xref>]. However, Hayakawa et al. [<xref ref-type="bibr" rid="B20">20</xref>] found that NAC inhibits NF-<italic>&#x003ba;</italic>Bactivation independently of its antioxidant function.</p><p>NF-<italic>&#x003ba;</italic>B has been shown to be important in the regulation of numerous genes, including manythat regulate the immune response, inflammation, cell proliferation, andapoptosis [<xref ref-type="bibr" rid="B21">21</xref>&#x02013;<xref ref-type="bibr" rid="B23">23</xref>]. Several inflammatory factorsthat are related to NF-<italic>&#x003ba;</italic>Bactivation have been identified, including TNF-<italic>&#x003b1;</italic>,interleukin (IL)-6, and IL-1<italic>&#x003b2;</italic> [<xref ref-type="bibr" rid="B23">23</xref>, <xref ref-type="bibr" rid="B24">24</xref>]. Several studies have usedgenetically modified mice to examine the role of NF-<italic>&#x003ba;</italic>B subunits in these functions. Knockout micehave been developed for all NF-<italic>&#x003ba;</italic>Bsubunits [<xref ref-type="bibr" rid="B25">25</xref>&#x02013;<xref ref-type="bibr" rid="B29">29</xref>]; in addition, knockouts forspecific tissues, such as the liver, have been developed [<xref ref-type="bibr" rid="B30">30</xref>, <xref ref-type="bibr" rid="B31">31</xref>]. Studies in which NF-<italic>&#x003ba;</italic>Bactivity has been inhibited by the deletion of one of its subunits, theinhibition of its translocation, or the expression of a dominant negative formof I<italic>&#x003ba;</italic>B have demonstrated a clear role for NF-<italic>&#x003ba;</italic>Bin inhibiting apoptosis by tumor necrosis factor-<italic>&#x003b1;</italic>(TNF-<italic>&#x003b1;</italic>) or other apoptosis inducers in several cell types [<xref ref-type="bibr" rid="B25">25</xref>, <xref ref-type="bibr" rid="B26">26</xref>, <xref ref-type="bibr" rid="B32">32</xref>&#x02013;<xref ref-type="bibr" rid="B36">36</xref>]. The deletion of the p65/relAsubunit leads to embryonic lethality at 15-16 days of gestation, due tohepatocyte apoptosis [<xref ref-type="bibr" rid="B26">26</xref>]. The deletion of the p50subunit leads to defects in the immune response involving B cells [<xref ref-type="bibr" rid="B25">25</xref>]. Hepatocyte apoptosis ishigher in p50 &#x02212;/&#x02212; mice [<xref ref-type="bibr" rid="B37">37</xref>, <xref ref-type="bibr" rid="B38">38</xref>], but it is not lethal as inthe p65 knockout. However, DNA synthesis and liver regeneration were notaffected by the absence of the p50 subunit following partial hepatectomy orcarbon tetrachloride treatment; increased levels of p65 may have compensatedfor the lack of p50 [<xref ref-type="bibr" rid="B39">39</xref>]. Similarly, the hepatic-specificexpression of a truncated I<italic>&#x003ba;</italic>B<italic>&#x003b1;</italic>superrepressor did not affect DNA synthesis, apoptosis, or liver regenerationfollowing partial hepatectomy, but led to increased apoptosis after treatmentwith TNF-<italic>&#x003b1;</italic> [<xref ref-type="bibr" rid="B40">40</xref>]. Also, the hepaticinflammatory response after ischemia/reperfusion was not altered in p50 &#x02212;/&#x02212;mice [<xref ref-type="bibr" rid="B41">41</xref>]. The deletion of p52 led todefects in humoral immunity and splenic architecture [<xref ref-type="bibr" rid="B28">28</xref>]. In RelB &#x02212;/&#x02212; mice, multiorganinflammation, impaired cellular immunity, and hematopoietic abnormalities wereobserved [<xref ref-type="bibr" rid="B29">29</xref>]. The deletion of c-rel led todefects in humoral immunity and in the proliferation of T cells in response tomitogens [<xref ref-type="bibr" rid="B27">27</xref>]. In addition, B cells lackingp50, RelB, or c-Rel (but not p52 or p65) exhibited decreased proliferation inresponse to lipopolysaccharide (LPS) [<xref ref-type="bibr" rid="B25">25</xref>, <xref ref-type="bibr" rid="B27">27</xref>, <xref ref-type="bibr" rid="B42">42</xref>&#x02013;<xref ref-type="bibr" rid="B44">44</xref>].</p></sec><sec sec-type="section" id="sec3"><title>3. HEPATIC ACTIVATION OF NF-<italic>&#x003ba;</italic>B BYPEROXISOME PROLIFERATORS</title><p>Our initial study examined whether peroxisome proliferators could activate NF-<italic>&#x003ba;</italic>Bin the liver (<xref ref-type="table" rid="tab1">Table 1</xref>) [<xref ref-type="bibr" rid="B45">45</xref>]. Rats were fed a dietcontaining 0.01% ciprofibrate; control rats received the same diet withoutciprofibrate. Animals were sacrificed 3, 6, or 10 days after startingtreatment. NF-<italic>&#x003ba;</italic>BDNA binding activity was monitored using electrophoretic mobility shift assays(EMSAs) with a radiolabeled NF-<italic>&#x003ba;</italic>Bprobe. Low levels of NF-<italic>&#x003ba;</italic>Bwere found in the liver nuclear extracts from control rats and remainedunchanged over the 10-day period. Three days after the initiation of treatment,an increase in nuclear NF-<italic>&#x003ba;</italic>BDNA binding activity was observed in treated versus control rats. NF-<italic>&#x003ba;</italic>Blevels continued to increase at six and ten days after treatment. Quantitativeradioanalytic image analysis indicated that the level of induction was nearlytwo-fold by day 3 and increased to 4-fold by day 10. Hepatocyte nuclear factor3 (HNF-3; foxa) is composed of a family of liver-enriched transcription factorsthat regulate the expression of many liver genes [<xref ref-type="bibr" rid="B46">46</xref>]. EMSAs with a radiolabeled HNF-3 binding motif derived from the rattransthyretin promoter showed that HNF-3 binding activity remained unchangedover the 10-day period in both treated and control rats. This indicates thatciprofibrate does not lead to a global, but rather a more restricted increasein hepatic transcription factor activity.</p><p>Following this initial observation, several additional studies have demonstrated that peroxisomeproliferators activate NF-<italic>&#x003ba;</italic>Bin the livers of rats and mice, species that are sensitive to the carcinogeniceffects of peroxisome proliferators (<xref ref-type="table" rid="tab1">Table 1</xref>). Ciprofibrate has been found to increase the DNA binding activity of NF-<italic>&#x003ba;</italic>Bin both rats and mice [<xref ref-type="bibr" rid="B16">16</xref>, <xref ref-type="bibr" rid="B17">17</xref>, <xref ref-type="bibr" rid="B38">38</xref>, <xref ref-type="bibr" rid="B48">57</xref>, <xref ref-type="bibr" rid="B47">58</xref>]. Wy-14,643 and dicamba increasedthe DNA binding activity of NF-<italic>&#x003ba;</italic>Bin rats and/or mice, while gemfibrozil and dibutyl phthalate activated NF-<italic>&#x003ba;</italic>Bto a lesser extent in rats and not at all timepoints [<xref ref-type="bibr" rid="B51">49</xref>, <xref ref-type="bibr" rid="B50">53</xref>, <xref ref-type="bibr" rid="B49">54</xref>, <xref ref-type="bibr" rid="B52">56</xref>]. Delerive et al. [<xref ref-type="bibr" rid="B53">52</xref>] observed that hepatic I<italic>&#x003ba;</italic>B<italic>&#x003b1;</italic>expression was increased by ciprofibrate in mice; this finding is somewhatdifficult to interpret since I<italic>&#x003ba;</italic>B is an NF-<italic>&#x003ba;</italic>B-regulatedgene but it is also associated with inhibiting NF-<italic>&#x003ba;</italic>B signaling. Nanji et al. [<xref ref-type="bibr" rid="B54">55</xref>] observed that clofibrate treatmentdid not affect the DNA binding activity of NF-<italic>&#x003ba;</italic>B (this study also observed that clofibratedecreased ethanol-induced NF-<italic>&#x003ba;</italic>B activation); however, this finding is also difficult to interpret since all rats were fed fish oil, which itself is a peroxisome proliferator [<xref ref-type="bibr" rid="B55">59</xref>]. All of the above studies examined NF-<italic>&#x003ba;</italic>Bactivation 3 or more days after beginning peroxisome proliferator administration. In short-term studies, Rusyn et al. observed that hepatic NF-<italic>&#x003ba;</italic>B DNA binding activity was increased shortlyafter a single dose of Wy-14,643, and that the increase was primarily due toincreased DNA binding activity in Kupffer cells and to the presence of NADPHoxidase in Kupffer cells [<xref ref-type="bibr" rid="B56">50</xref>, <xref ref-type="bibr" rid="B57">51</xref>]. However, after a single doseof BR-931 [<xref ref-type="bibr" rid="B58">47</xref>] or nafenopin [<xref ref-type="bibr" rid="B59">48</xref>], the DNA binding activity of NF-<italic>&#x003ba;</italic>Bin liver was not increased after 0.5&#x02013;24 hours following exposure. Takentogether, these data suggest that the early activation of hepatic NF-<italic>&#x003ba;</italic>Boccurs in Kupffer cells, while the activation in hepatocytes does not appearuntil 3 days or later after the beginning of peroxisome proliferator administration. Finally, the presence of PPAR<italic>&#x003b1;</italic>is necessary for these changes in NF-<italic>&#x003ba;</italic>Bactivation to occur, since neither Wy-14,643 nor ciprofibrate affected NF-<italic>&#x003ba;</italic>Bactivation in PPAR<italic>&#x003b1;</italic>-deficientmice [<xref ref-type="bibr" rid="B53">52</xref>, <xref ref-type="bibr" rid="B52">56</xref>].</p><p>The activation of hepatic NF-<italic>&#x003ba;</italic>B had also been examined in vitro. EMSAs demonstrated NF-<italic>&#x003ba;</italic>Binduction by ciprofibrate in peroxisome proliferator-responsive H4IIEC3 rathepatoma cells but not in peroxisome proliferator-insensitive HepG2 humanhepatoma cell lines [<xref ref-type="bibr" rid="B18">18</xref>]. In addition, stably transfectedNF-<italic>&#x003ba;</italic>B-regulated reporter genes were activated by ciprofibrate in H4IIEC3 cells. These changeswere observed after 72 hours of exposure, with the increase in fatty acyl CoA oxidaseactivity being observed at 24 hours, the first time point tested. This reportergene activation was blocked by the antioxidants <italic>N</italic>-acetylcysteine andvitamin E. West et al. [<xref ref-type="bibr" rid="B60">60</xref>] examined the activation of NF-<italic>&#x003ba;</italic>Bin cultured mouse hepatocytes in response to nafenopin. After a 4-hourexposure, the DNA binding activity of NF-<italic>&#x003ba;</italic>B was increased. Using human HuH7 hepatomacells, Kleemann et al. [<xref ref-type="bibr" rid="B61">61</xref>] found that Wy-14,643increased I<italic>&#x003ba;</italic>B<italic>&#x003b1;</italic>protein levels and decreased the nuclear translocation of NF-<italic>&#x003ba;</italic>B. In addition, the peroxisome proliferatorsWy-14,643 and fenofibrate decreased interleukin- (IL-) 1<italic>&#x003b2;</italic>-induced C-reactive protein expression. Delerive et al. [<xref ref-type="bibr" rid="B53">52</xref>] also found that I<italic>&#x003ba;</italic>B<italic>&#x003b1;</italic>expression and protein levels were increased by Wy-14,643 in primary humanhepatocytes and that IL-1<italic>&#x003b2;</italic>-induced cyclooxygenase- (COX-) 2 protein levels weredecreased by Wy-14,643.  These studiessuggest that rodent hepatic NF-<italic>&#x003ba;</italic>Bactivation is due to, at least in part, activation in hepatocytes. In human livercells and cell lines, however, NF-<italic>&#x003ba;</italic>Bactivation is not affected or is decreased by peroxisome proliferatoradministration.</p></sec><sec sec-type="section" id="sec4"><title>4. IMPORTANCE OF NF-<italic>&#x003ba;</italic>B INHEPATOCARCINOGENESIS BYPEROXISOME PROLIFERATORS</title><p>An important question is whether NF-<italic>&#x003ba;</italic>Bactivation by peroxisome proliferators is necessary for carcinogenesis by peroxisomeproliferators, as well as the induction of changes in cell proliferation,apoptosis, and gene expression. If NF-<italic>&#x003ba;</italic>Bactivation does contribute to the promoting activity of peroxisome proliferators,one would predict that if the activity of NF-<italic>&#x003ba;</italic>B were diminished, the enhancement of cellproliferation and carcinogenesis as well as the inhibition of apoptosis by peroxisomeproliferators would be decreased. Several studies have examined this question,using mice in which the p50 subunit of NF-<italic>&#x003ba;</italic>B has been deleted. In the first study, theeffect of p50 deletion on cell proliferation, apoptosis, and related geneexpression was examined [<xref ref-type="bibr" rid="B38">38</xref>]. Wild-type and p50 &#x02212;/&#x02212; micewere fed a diet with or without 0.01% ciprofibrate for 10 days. NF-<italic>&#x003ba;</italic>BDNA binding activity was present and increased after ciprofibrate treatment inwild-type mice, but was not detected in p50 &#x02212;/&#x02212; mice. The untreated p50 &#x02212;/&#x02212;mice had a higher level of hepatic cell proliferation, as measured by BrdUlabeling, than did untreated wild-type mice. However, the increase inproliferation was greater in ciprofibrate-fed wild-type mice than inciprofibrate-fed p50 &#x02212;/&#x02212; mice. The apoptotic index was low in wild-type mice inthe presence or absence of ciprofibrate. Apoptosis was increased in untreatedp50 &#x02212;/&#x02212; mice compared to wild-type mice; apoptosis was reduced in p50 &#x02212;/&#x02212; miceafter ciprofibrate feeding. Because increased cell proliferation in the liveris associated with increased activator protein-1 (AP-1) activity, theexpression of genes in the Fos and Jun families of transcription factors wasexamined. The c-Jun and JunB mRNA levels were higher in untreated p50 &#x02212;/&#x02212; micethan in untreated wild-type mice; c-Jun mRNA levels increased whereas JunB mRNAlevels decreased in both groups after ciprofibrate treatment. However, c-Junand JunB protein levels were the same in untreated wild-type and p50 &#x02212;/&#x02212; mice,and increased in both groups after ciprofibrate treatment. Apoptosis-relatedgene expression was also examined, and several apoptosis-related mRNAs werehigher in untreated p50 &#x02212;/&#x02212; mice compared to untreated wild-type mice;expression of these genes increased in both groups after ciprofibratetreatment. These data indicate that NF-<italic>&#x003ba;</italic>Bcontributes to the proliferative and apoptotic changes that occur in the liverin response to ciprofibrate.</p><p>The role of NF-<italic>&#x003ba;</italic>B in the inhibition of apoptosis by peroxisome proliferators has also beenexamined in vitro. Using primary rat hepatocytes, Cosulich et al. [<xref ref-type="bibr" rid="B62">62</xref>] infected cells with anadenovirus containing a dominant negative form of IKK2. The dominant negativeIKK2 induced apoptosis in the hepatocytes, which could not be inhibited by theaddition of nafenopin. These data indicate that NF-<italic>&#x003ba;</italic>B activation is essential for the inhibition ofapoptosis by peroxisome proliferators.</p><p>The role of NF-<italic>&#x003ba;</italic>B in the promotion of hepatocarcinogenesis by Wy-14,643 has been examined, usingp50 &#x02212;/&#x02212; mice [<xref ref-type="bibr" rid="B63">63</xref>]. The p50 &#x02212;/&#x02212; and wild-typemice were first administered diethylnitrosamine (DEN) as an initiating agent. Micewere then fed a control diet or a diet containing 0.05% Wy-14,643 for 38 weeks. As expected, wild-type mice receiving DEN only developed a low incidence oftumors, and the majority of wild-type mice receiving both DEN and Wy-14,643developed tumors. However, no tumors were seen in any of the p50 &#x02212;/&#x02212; mice. Treatmentwith DEN/Wy-14,643 increased both cell proliferation and apoptosis in wild-typeand p50 &#x02212;/&#x02212; mice; DEN treatment alone had no effect. In the DEN/Wy-14,643-treatedmice, cell proliferation and apoptosis were slightly lower in the p50 &#x02212;/&#x02212; micethan in the wild-type mice. These data demonstrate that NF-<italic>&#x003ba;</italic>Bis involved in the promotion of hepatic tumors by the peroxisome proliferator Wy-14,643;however, in this study, the difference in tumor incidence could not beattributed to alterations in either cell proliferation or apoptosis.</p></sec><sec sec-type="section" id="sec5"><title>5. MECHANISMS BY WHICH PEROXISOMEPROLIFERATORS INFLUENCE NF-<italic>&#x003ba;</italic>B ACTIVATION</title><p>The studies discussed above showed that peroxisome proliferators activate hepatic NF-<italic>&#x003ba;</italic>B,except possibly for very short exposure periods, and that NF-<italic>&#x003ba;</italic>B activation is necessary for the promotingactivity and associated biochemical activities of peroxisome proliferators. Themechanisms by which peroxisome proliferators activate NF-<italic>&#x003ba;</italic>B have been examined in several studies. Thesestudies can be divided into two main groups: (1) those taking place in nonhepaticcells or nonrodent hepatocytes, or in which the exposure time was short; and (2)those in liver, in which the exposure time was longer, usually greater than oneweek. The former studies involved alterations in NF-<italic>&#x003ba;</italic>B in the absence of changes in gene expressionbrought about by PPAR<italic>&#x003b1;</italic>activation in rodent liver. For the longer studies, however, changes in geneexpression and cell metabolism in response to PPAR<italic>&#x003b1;</italic>activation have occurred. These include the induction of the peroxisomal <italic>&#x003b2;</italic>-oxidationpathway including fatty acyl CoA oxidase (FAO) and the cytochrome P-450 4A (CYP4A)family. FAO produces hydrogen peroxide as a by-product, and CYP4A may alsoproduce reactive oxygen species. PPAR<italic>&#x003b1;</italic>activation also results in a decrease in the activities of cellular antioxidantenzymes such as glutathione peroxidase, glutathione S-transferase, andDT-diaphorase, and in the concentrations of cellular antioxidants such asvitamin E [<xref ref-type="bibr" rid="B7">7</xref>]. Therefore, oxidative stressmay be an important mechanism in the activation of NF-<italic>&#x003ba;</italic>B by peroxisome proliferators.</p><p>In tissues that are not responsive to the peroxisome proliferative andcarcinogenic effects to peroxisome proliferators, such as human hepatocytes andnonhepatocyte tissues and cells, the administration of PPAR<italic>&#x003b1;</italic>activators clearly leads to a decrease in NF-<italic>&#x003ba;</italic>B activation and NF-<italic>&#x003ba;</italic>B-regulated gene expression. These includekidney cells in vitro [<xref ref-type="bibr" rid="B64">64</xref>], human aortic smooth musclecells [<xref ref-type="bibr" rid="B53">52</xref>, <xref ref-type="bibr" rid="B65">65</xref>], human HuH7 hepatoma cells [<xref ref-type="bibr" rid="B61">61</xref>], primary human hepatocytes [<xref ref-type="bibr" rid="B53">52</xref>], human endothelial cells [<xref ref-type="bibr" rid="B66">66</xref>], Cos-1 cells [<xref ref-type="bibr" rid="B67">67</xref>], and mouse splenocytes in vivo [<xref ref-type="bibr" rid="B68">68</xref>]. In these cases, PPAR<italic>&#x003b1;</italic>decreased NF-<italic>&#x003ba;</italic>Bactivation by the direct interaction with p65 [<xref ref-type="bibr" rid="B65">65</xref>] and/or by increasing I<italic>&#x003ba;</italic>B<italic>&#x003b1;</italic>expression [<xref ref-type="bibr" rid="B53">52</xref>]. The administration of peroxisomeproliferators also decreased the expression and/or protein levels of NF-<italic>&#x003ba;</italic>B-regulatedinflammatory genes, including IL-6 [<xref ref-type="bibr" rid="B65">65</xref>, <xref ref-type="bibr" rid="B68">68</xref>], IL-12 [<xref ref-type="bibr" rid="B68">68</xref>], C-reactive protein [<xref ref-type="bibr" rid="B61">61</xref>], vascular cell adhesion molecule-1(VCAM-1) [<xref ref-type="bibr" rid="B66">66</xref>], and COX-2 [<xref ref-type="bibr" rid="B67">67</xref>]. On the other hand,inhibition of the NF-<italic>&#x003ba;</italic>B signaling pathway by inactivating the NF-<italic>&#x003ba;</italic>B essential modulator (NEMO) gene in rodent liver leads to a decrease in the expression of PPAR<italic>&#x003b1;</italic>[<xref ref-type="bibr" rid="B69">69</xref>].</p><p>Several lines of evidence support the hypothesis that NF-<italic>&#x003ba;</italic>B activation after one week or more of exposureto peroxisome proliferators is mediated by oxidative stress produced by peroxisomeproliferators. First, overexpression of the hydrogen peroxide-producing enzymethat is induced by peroxisome proliferators, FAO, is sufficient to activate NF-<italic>&#x003ba;</italic>Bin Cos-1 cells [<xref ref-type="bibr" rid="B70">70</xref>]. In addition, FAO overexpression in Cos-1 cells, in thepresence of an H<sub>2</sub>O<sub>2</sub>-generating substrate, can activate anNF-<italic>&#x003ba;</italic>B-regulatedreporter gene. Electrophoretic mobility shift assays further demonstrated thatFAO expression increases nuclear NF-<italic>&#x003ba;</italic>BDNA binding activity in a dose-dependent manner. The antioxidants vitamin E andcatalase can inhibit this activation [<xref ref-type="bibr" rid="B70">70</xref>].</p><p>Second, overexpression of the hydrogen peroxide-detoxifying enzyme catalase in thelivers of transgenic mice inhibits the activation of NF-<italic>&#x003ba;</italic>B by ciprofibrate [<xref ref-type="bibr" rid="B16">16</xref>]. In this study, mice overexpressingcatalase in the liver or non-transgenic littermates were fed either 0.01%ciprofibrate or a control diet for 21 days. FAO activity was not significantlyaffected by catalase overexpression although the ratio of FAO to catalase wassignificantly decreased in transgenic animals. Ciprofibrate increased NF-<italic>&#x003ba;</italic>BDNA binding activity in the livers of non-transgenic mice, but this increasewas inhibited by catalase overexpression. In addition, the ciprofibrate-inducedincrease in hepatocyte proliferation was decreased by catalase overexpression,indicating a possible role for NF-<italic>&#x003ba;</italic>Bin cell proliferation by peroxisome proliferators.</p><p>Third, studies in species with different responses to peroxisome proliferators supporta role for oxidative stress in NF-<italic>&#x003ba;</italic>Bactivation. Rats and mice are sensitive to the hepatocarcinogenic and cellproliferation-inducing effects of peroxisome proliferators whereas otherspecies, such as Syrian hamsters, are not [<xref ref-type="bibr" rid="B71">71</xref>, <xref ref-type="bibr" rid="B72">72</xref>]. Therefore, we examined theeffects of three different peroxisome proliferators on antioxidant enzymes,antioxidant vitamins, and NF-<italic>&#x003ba;</italic>Bactivation in rats and Syrian hamsters [<xref ref-type="bibr" rid="B50">53</xref>, <xref ref-type="bibr" rid="B73">73</xref>, <xref ref-type="bibr" rid="B74">74</xref>]. The peroxisome proliferatorsWy-14,643, gemfibrozil, and dibutyl phthalate were administered to animals for6, 34, or 90 days. In rats, decreases in glutathione reductase (GR), glutathioneS-transferase (GST), and selenium-dependent glutathione peroxidase (GPx) wereobserved following peroxisome proliferator treatment at various time points. Inhamsters, a higher basal level of activities for GR, GST, and selenium GPx wasobserved as compared to rats. In addition, hamsters showed decreases in GR andGST activities following peroxisome proliferator treatment. Interestingly, selenium-GPxactivity was increased in hamsters following peroxisome proliferator treatment. Treatment for 90 days with Wy-14,643 resulted in no change in GPx1 mRNA in ratsand increased GPx1 mRNA in hamsters. In both rats and hamsters treated withWy-14,643, we observed decreases in <italic>&#x003b1;</italic>-tocopherolcontent and total superoxide dismutase (SOD) activity. Conversely, DT-diaphoraseactivity was decreased following Wy-14,643 treatment in rats at all time pointsand doses, but only sporadically affected in hamsters. Rats and hamsterstreated with DBP demonstrated increased SOD activity at 6 days; however, in therat, DBP decreased SOD activity at 90 days and <italic>&#x003b1;</italic>-tocopherolcontent was decreased throughout. In gemfibrozil-treated rats and hamsters, adecrease in <italic>&#x003b1;</italic>-tocopherol content and an increase inDT-diaphorase activity were observed. In either species, no consistent trendwas observed in total ascorbic acid content after treatment with any of the peroxisomeproliferators. NF-<italic>&#x003ba;</italic>B activation was evaluated by EMSA. Wy-14,643 increased the DNA binding activity of NF-<italic>&#x003ba;</italic>B at all three timepoints in rats and produced the highest activation of the three chemicals tested (<xref ref-type="table" rid="tab1">Table 1</xref>). Gemfibrozil and DBP increased NF-<italic>&#x003ba;</italic>B activation to a less extent in rats and not at all times. There were no differences in hepatic NF-<italic>&#x003ba;</italic>Blevels between control hamsters and hamsters treated with any of the peroxisomeproliferators. These studies show that NF-<italic>&#x003ba;</italic>B is not activated by peroxisome proliferatorsin hamsters, which have much higher levels of the antioxidant enzymesglutathione peroxidase, glutathione S-transferase, glutathione reductase, andDT-diaphorase, and which are not responsive to the carcinogenic effects of theperoxisome proliferators.</p><p>Finally, the antioxidant, vitamin E, inhibits ciprofibrate-induced NF-<italic>&#x003ba;</italic>B activation, both in vivo and in vitro. In an in vitro study [<xref ref-type="bibr" rid="B18">18</xref>], NF-<italic>&#x003ba;</italic>B-regulated reporter genes were stably transfectedinto rat hepatoma H4IIEC3 cells. The ciprofibrate-induced increase inluciferase activity after 72 hours of exposure was blocked by the addition of <italic>&#x003b1;</italic>-tocopheryl acetate. N-acetylcysteine also inhibited the ciprofibrate-induced increase. In the in vivo study [<xref ref-type="bibr" rid="B17">17</xref>], thirty-six male Sprague-Dawley rats were fed a purified dietcontaining varying levels of vitamin E (10, 50, 250 ppm <italic>&#x003b1;</italic>-tocopheryl acetate). After 28 days, sevenanimals per vitamin E group received 0.01% ciprofibrate in the diet for 10days. Increased dietary <italic>&#x003b1;</italic>-tocopherol acetate inhibited CIP-induced NF-<italic>&#x003ba;</italic>BDNA binding. Since NF-<italic>&#x003ba;</italic>B translocates to the nucleus upon the phosphorylation and degradation of I<italic>&#x003ba;</italic>B,we also used western blots to measure cytosolic protein levels of I<italic>&#x003ba;</italic>B<italic>&#x003b1;</italic>,I<italic>&#x003ba;</italic>B<italic>&#x003b2;</italic>, and I<italic>&#x003ba;</italic>B kinases: IKK<italic>&#x003b1;</italic> and IKK<italic>&#x003b2;</italic>. However, I<italic>&#x003ba;</italic>B<italic>&#x003b1;</italic>protein levels were decreased in all three CIP-treated groups, with the 10 ppmvitamin E diet also decreasing I<italic>&#x003ba;</italic>B<italic>&#x003b1;</italic> levels in control rats. No difference in I<italic>&#x003ba;</italic>B<italic>&#x003b2;</italic>protein levels was observed among any of the groups. The CIP-treated ratsgenerally had lower protein levels of IKK<italic>&#x003b1;</italic> and IKK<italic>&#x003b2;</italic>.</p><p>An important question is whether vitamin E is exerting some of its effects by blockingthe activation of NF-<italic>&#x003ba;</italic>B. The use of NF-<italic>&#x003ba;</italic>B knockout models may provide answers to this question. A study has addressedthis question by examining if the inhibition of NF-<italic>&#x003ba;</italic>B by vitamin E is necessary for vitamin E'seffects on the induction of cell proliferation by the peroxisome proliferatorciprofibrate and on the inhibition of apoptosis by ciprofibrate [<xref ref-type="bibr" rid="B48">57</xref>]. Wild-type and p50 &#x02212;/&#x02212; micewere administered ciprofibrate and one of two levels of vitamin E (10 or 250 mg/kg diet). Vitamin E inhibited ciprofibrate-induced cell proliferation onlyin the p50 &#x02212;/&#x02212; mice. Dietary vitamin E also increased apoptosis and increasedthe GSH/GSSG ratio in both wild-type and p50 &#x02212;/&#x02212; mice. This study suggests thatvitamin E does not act by blocking NF-<italic>&#x003ba;</italic>Bactivation, indicating that vitamin E is acting by other molecular mechanisms.</p></sec><sec sec-type="section" id="sec6"><title>6. CONCLUSIONS</title><p>In summary, the administration of most peroxisome proliferators leads to theactivation of NF-<italic>&#x003ba;</italic>Bin the liver of rats and mice. This activation appears to be necessary for the tumor-promotingactivity and for the induction of cell proliferation by peroxisomeproliferators. The activation of NF-<italic>&#x003ba;</italic>Bappears to be mediated at least in part by the induction of oxidative stress byperoxisome proliferators. Future studies examining the mechanisms by which NF-<italic>&#x003ba;</italic>Bis altered by PPAR<italic>&#x003b1;</italic>activation will need to clearly distinguish between those changes brought aboutdirectly by PPAR<italic>&#x003b1;</italic>and those brought about as a result of changes in gene expression through PPAR<italic>&#x003b1;</italic> (such as the peroxisomal <italic>&#x003b2;</italic>-oxidation pathway). Theidentity of specific NF-<italic>&#x003ba;</italic>B-regulatedgenes after the administration of peroxisome proliferators, particularly genesrelated to cell proliferation and apoptosis, will also need to be determined infuture studies.</p></sec></body><back><ref-list><ref id="B1"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rao</surname><given-names>MS</given-names></name><name><surname>Reddy</surname><given-names>JK</given-names></name></person-group><article-title>Peroxisome proliferation and hepatocarcinogenesis</article-title><source><italic>Carcinogenesis</italic></source><year>1987</year><volume>8</volume><issue>5</issue><fpage>631</fpage><lpage>636</lpage><pub-id pub-id-type="pmid">3555880</pub-id></citation></ref><ref id="B2"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cattley</surname><given-names>RC</given-names></name><name><surname>DeLuca</surname><given-names>J</given-names></name><name><surname>Elcombe</surname><given-names>C</given-names></name><etal/></person-group><article-title>Do peroxisome proliferating compounds pose a hepatocarcinogenic hazard to humans?</article-title><source><italic>Regulatory Toxicology and Pharmacology</italic></source><year>1998</year><volume>27</volume><issue>1</issue><fpage>47</fpage><lpage>60</lpage></citation></ref><ref id="B3"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Peters</surname><given-names>JM</given-names></name><name><surname>Cattley</surname><given-names>RC</given-names></name><name><surname>Gonzalez</surname><given-names>FJ</given-names></name></person-group><article-title>Role of PPAR<italic>&#x003b1;</italic> in the mechanism of action of the nongenotoxic carcinogen and peroxisome proliferator Wy-14,643</article-title><source><italic>Carcinogenesis</italic></source><year>1997</year><volume>18</volume><issue>11</issue><fpage>2029</fpage><lpage>2033</lpage><pub-id pub-id-type="pmid">9395198</pub-id></citation></ref><ref id="B4"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schoonjans</surname><given-names>K</given-names></name><name><surname>Staels</surname><given-names>B</given-names></name><name><surname>Auwerx</surname><given-names>J</given-names></name></person-group><article-title>Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression</article-title><source><italic>Journal of Lipid Research</italic></source><year>1996</year><volume>37</volume><issue>5</issue><fpage>907</fpage><lpage>925</lpage><pub-id pub-id-type="pmid">8725145</pub-id></citation></ref><ref id="B5"><label>5</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Eacho</surname><given-names>PI</given-names></name><name><surname>Feller</surname><given-names>DR</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Witiak</surname><given-names>DT</given-names></name><name><surname>Newman</surname><given-names>HAI</given-names></name><name><surname>Feller</surname><given-names>DR</given-names></name></person-group><article-title>Hepatic peroxisome proliferation induced by hypolipidemic drugs and other chemicals</article-title><source><italic>Antilipidemic Drugs, Medicinal, Chemical and Biochemical Aspects</italic></source><year>1991</year><publisher-loc>Amsterdam, The Netherlands</publisher-loc><publisher-name>Elsevier Science</publisher-name><fpage>375</fpage><lpage>426</lpage></citation></ref><ref id="B6"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lock</surname><given-names>EA</given-names></name><name><surname>Mitchell</surname><given-names>AM</given-names></name><name><surname>Elcombe</surname><given-names>CR</given-names></name></person-group><article-title>Biochemical mechanisms of induction of hepatic peroxisome proliferation</article-title><source><italic>Annual Review of Pharmacology and Toxicology</italic></source><year>1989</year><volume>29</volume><fpage>145</fpage><lpage>163</lpage></citation></ref><ref id="B7"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>O'Brien</surname><given-names>ML</given-names></name><name><surname>Spear</surname><given-names>BT</given-names></name><name><surname>Glauert</surname><given-names>HP</given-names></name></person-group><article-title>Role of oxidative stress in peroxisome proliferator-mediated carcinogenesis</article-title><source><italic>Critical Reviews in Toxicology</italic></source><year>2005</year><volume>35</volume><issue>1</issue><fpage>61</fpage><lpage>88</lpage><pub-id pub-id-type="pmid">15742903</pub-id></citation></ref><ref id="B8"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Karin</surname><given-names>M</given-names></name><name><surname>Lin</surname><given-names>A</given-names></name></person-group><article-title>NF-<italic>&#x003ba;</italic>B at the crossroads of life and death</article-title><source><italic>Nature Immunology</italic></source><year>2002</year><volume>3</volume><issue>3</issue><fpage>221</fpage><lpage>227</lpage><pub-id pub-id-type="pmid">11875461</pub-id></citation></ref><ref id="B9"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Karin</surname><given-names>M</given-names></name><name><surname>Delhase</surname><given-names>M</given-names></name></person-group><article-title>The I<italic>&#x003ba;</italic>B kinase (IKK) and NF-<italic>&#x003ba;</italic>B: key elements of proinflammatory signalling</article-title><source><italic>Seminars in Immunology</italic></source><year>2000</year><volume>12</volume><issue>1</issue><fpage>85</fpage><lpage>98</lpage><pub-id pub-id-type="pmid">10723801</pub-id></citation></ref><ref id="B10"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zandi</surname><given-names>E</given-names></name><name><surname>Rothwarf</surname><given-names>DM</given-names></name><name><surname>Delhase</surname><given-names>M</given-names></name><name><surname>Hayakawa</surname><given-names>M</given-names></name><name><surname>Karin</surname><given-names>M</given-names></name></person-group><article-title>The I<italic>&#x003ba;</italic>B kinase complex (IKK) contains two kinase subunits, IKK<italic>&#x003b1;</italic> and IKK<italic>&#x003b2;</italic>, necessary for I<italic>&#x003ba;</italic>B phosphorylation and NF-<italic>&#x003ba;</italic>B activation</article-title><source><italic>Cell</italic></source><year>1997</year><volume>91</volume><issue>2</issue><fpage>243</fpage><lpage>252</lpage><pub-id pub-id-type="pmid">9346241</pub-id></citation></ref><ref id="B11"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Karin</surname><given-names>M</given-names></name></person-group><article-title>NF-<italic>&#x003ba;</italic>B and cancer: mechanisms and targets</article-title><source><italic>Molecular Carcinogenesis</italic></source><year>2006</year><volume>45</volume><issue>6</issue><fpage>355</fpage><lpage>361</lpage><pub-id pub-id-type="pmid">16673382</pub-id></citation></ref><ref id="B12"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Staal</surname><given-names>FJT</given-names></name><name><surname>Roederer</surname><given-names>M</given-names></name><name><surname>Herzenberg</surname><given-names>LA</given-names></name><name><surname>Herzenberg</surname><given-names>LA</given-names></name></person-group><article-title>Intracellular thiols regulate activation of nuclear factor <italic>&#x003ba;</italic>B and transcription of human immunodeficiency virus</article-title><source><italic>Proceedings of the National Academy of Sciences of the United States of America</italic></source><year>1990</year><volume>87</volume><issue>24</issue><fpage>9943</fpage><lpage>9947</lpage><pub-id pub-id-type="pmid">2263644</pub-id></citation></ref><ref id="B13"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schreck</surname><given-names>R</given-names></name><name><surname>Rieber</surname><given-names>P</given-names></name><name><surname>Baeuerle</surname><given-names>PA</given-names></name></person-group><article-title>Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-<italic>&#x003ba;</italic>B transcription factor and HIV-1</article-title><source><italic>The EMBO Journal</italic></source><year>1991</year><volume>10</volume><issue>8</issue><fpage>2247</fpage><lpage>2258</lpage><pub-id pub-id-type="pmid">2065663</pub-id></citation></ref><ref id="B14"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schreck</surname><given-names>R</given-names></name><name><surname>Albermann</surname><given-names>K</given-names></name><name><surname>Baeuerle</surname><given-names>PA</given-names></name></person-group><article-title>Nuclear factor <italic>&#x003ba;</italic>B: an oxidative stress-responsive transcription factor of eukaryotic cells (a review)</article-title><source><italic>Free Radical Research Communications</italic></source><year>1992</year><volume>17</volume><issue>4</issue><fpage>221</fpage><lpage>237</lpage><pub-id pub-id-type="pmid">1473734</pub-id></citation></ref><ref id="B15"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Meyer</surname><given-names>M</given-names></name><name><surname>Schreck</surname><given-names>R</given-names></name><name><surname>Baeuerle</surname><given-names>PA</given-names></name></person-group><article-title>H<sub>2</sub>O<sub>2</sub> and antioxidants have opposite effects on activation of NF-<italic>&#x003ba;</italic>B and AP-1 in intact cells: AP-1 as secondary antioxidant-responsive factor</article-title><source><italic>The EMBO Journal</italic></source><year>1993</year><volume>12</volume><issue>5</issue><fpage>2005</fpage><lpage>2015</lpage><pub-id pub-id-type="pmid">8491191</pub-id></citation></ref><ref id="B16"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nilakantan</surname><given-names>V</given-names></name><name><surname>Spear</surname><given-names>BT</given-names></name><name><surname>Glauert</surname><given-names>HP</given-names></name></person-group><article-title>Liver-specific catalase expression in transgenic mice inhibits NF-<italic>&#x003ba;</italic>B activation and DNA synthesis induced by the peroxisome proliferator ciprofibrate</article-title><source><italic>Carcinogenesis</italic></source><year>1998</year><volume>19</volume><issue>4</issue><fpage>631</fpage><lpage>637</lpage><pub-id pub-id-type="pmid">9600348</pub-id></citation></ref><ref id="B17"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Calfee-Mason</surname><given-names>KG</given-names></name><name><surname>Spear</surname><given-names>BT</given-names></name><name><surname>Glauert</surname><given-names>HP</given-names></name></person-group><article-title>Effects of vitamin E on the NF-<italic>&#x003ba;</italic>B pathway in rats treated with the peroxisome proliferator, ciprofibrate</article-title><source><italic>Toxicology and Applied Pharmacology</italic></source><year>2004</year><volume>199</volume><issue>1</issue><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">15289085</pub-id></citation></ref><ref id="B18"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Glauert</surname><given-names>HP</given-names></name><name><surname>Spear</surname><given-names>BT</given-names></name></person-group><article-title>Activation of nuclear factor-<italic>&#x003ba;</italic>B by the peroxisome proliferator ciprofibrate in H4IIEC3 rat hepatoma cells and its inhibition by the antioxidants <italic>N</italic>-acetylcysteine and vitamin E</article-title><source><italic>Biochemical Pharmacology</italic></source><year>2000</year><volume>59</volume><issue>4</issue><fpage>427</fpage><lpage>434</lpage><pub-id pub-id-type="pmid">10644051</pub-id></citation></ref><ref id="B19"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>KN</given-names></name><name><surname>Amstad</surname><given-names>P</given-names></name><name><surname>Cerutti</surname><given-names>P</given-names></name><name><surname>Baeuerle</surname><given-names>PA</given-names></name></person-group><article-title>The roles of hydrogen peroxide and superoxide as messengers in the activation of transcription factor NF-<italic>&#x003ba;</italic>B</article-title><source><italic>Chemistry &#x00026; Biology</italic></source><year>1995</year><volume>2</volume><issue>1</issue><fpage>13</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">9383399</pub-id></citation></ref><ref id="B20"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hayakawa</surname><given-names>M</given-names></name><name><surname>Miyashita</surname><given-names>H</given-names></name><name><surname>Sakamoto</surname><given-names>I</given-names></name><etal/></person-group><article-title>Evidence that reactive oxygen species do not mediate NF-<italic>&#x003ba;</italic>B activation</article-title><source><italic>The EMBO Journal</italic></source><year>2003</year><volume>22</volume><issue>13</issue><fpage>3356</fpage><lpage>3366</lpage><pub-id pub-id-type="pmid">12839997</pub-id></citation></ref><ref id="B21"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>FitzGerald</surname><given-names>MJ</given-names></name><name><surname>Webber</surname><given-names>EM</given-names></name><name><surname>Donovan</surname><given-names>JR</given-names></name><name><surname>Fausto</surname><given-names>N</given-names></name></person-group><article-title>Rapid DNA binding by nuclear factor <italic>&#x003ba;</italic>B in hepatocytes at the start of liver regeneration</article-title><source><italic>Cell Growth &#x00026; Differentiation</italic></source><year>1995</year><volume>6</volume><issue>4</issue><fpage>417</fpage><lpage>427</lpage><pub-id pub-id-type="pmid">7794809</pub-id></citation></ref><ref id="B22"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Beg</surname><given-names>AA</given-names></name><name><surname>Sha</surname><given-names>WC</given-names></name><name><surname>Bronson</surname><given-names>RT</given-names></name><name><surname>Ghosh</surname><given-names>S</given-names></name><name><surname>Baltimore</surname><given-names>D</given-names></name></person-group><article-title>Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-<italic>&#x003ba;</italic>B</article-title><source><italic>Nature</italic></source><year>1995</year><volume>376</volume><issue>6536</issue><fpage>167</fpage><lpage>170</lpage><pub-id pub-id-type="pmid">7603567</pub-id></citation></ref><ref id="B23"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vanden Berghe</surname><given-names>W</given-names></name><name><surname>Vermeulen</surname><given-names>L</given-names></name><name><surname>Delerive</surname><given-names>P</given-names></name><name><surname>De Bosscher</surname><given-names>K</given-names></name><name><surname>Staels</surname><given-names>B</given-names></name><name><surname>Haegeman</surname><given-names>G</given-names></name></person-group><article-title>A paradigm for gene regulation: inflammation, NF-<italic>&#x003ba;</italic>B and PPAR</article-title><source><italic>Advances in Experimental Medicine and Biology</italic></source><year>2003</year><volume>544</volume><fpage>181</fpage><lpage>196</lpage><pub-id pub-id-type="pmid">14713228</pub-id></citation></ref><ref id="B24"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Maeda</surname><given-names>S</given-names></name><name><surname>Omata</surname><given-names>M</given-names></name></person-group><article-title>Inflammation and cancer: role of nuclear factor-kappaB activation</article-title><source><italic>Cancer Science</italic></source><year>2008</year><volume>99</volume><issue>5</issue><fpage>836</fpage><lpage>842</lpage><pub-id pub-id-type="pmid">18294278</pub-id></citation></ref><ref id="B25"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sha</surname><given-names>WC</given-names></name><name><surname>Liou</surname><given-names>H-C</given-names></name><name><surname>Tuomanen</surname><given-names>EI</given-names></name><name><surname>Baltimore</surname><given-names>D</given-names></name></person-group><article-title>Targeted disruption of the p50 subunit of NF-<italic>&#x003ba;</italic>B leads to multifocal defects in immune responses</article-title><source><italic>Cell</italic></source><year>1995</year><volume>80</volume><issue>2</issue><fpage>321</fpage><lpage>330</lpage><pub-id pub-id-type="pmid">7834752</pub-id></citation></ref><ref id="B26"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Beg</surname><given-names>AA</given-names></name><name><surname>Sha</surname><given-names>WC</given-names></name><name><surname>Bronson</surname><given-names>RT</given-names></name><name><surname>Ghosh</surname><given-names>S</given-names></name><name><surname>Baltimore</surname><given-names>D</given-names></name></person-group><article-title>Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-<italic>&#x003ba;</italic>B</article-title><source><italic>Nature</italic></source><year>1995</year><volume>376</volume><issue>6536</issue><fpage>167</fpage><lpage>170</lpage><pub-id pub-id-type="pmid">7603567</pub-id></citation></ref><ref id="B27"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kontgen</surname><given-names>F</given-names></name><name><surname>Grumont</surname><given-names>RJ</given-names></name><name><surname>Strasser</surname><given-names>A</given-names></name><etal/></person-group><article-title>Mice lacking the c-rel proto-oncogene exhibit defects in lymphocyte proliferation, humoral immunity, and interleukin-2 expression</article-title><source><italic>Genes &#x00026; Development</italic></source><year>1995</year><volume>9</volume><issue>16</issue><fpage>1965</fpage><lpage>1977</lpage><pub-id pub-id-type="pmid">7649478</pub-id></citation></ref><ref id="B28"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Franzoso</surname><given-names>G</given-names></name><name><surname>Carlson</surname><given-names>L</given-names></name><name><surname>Poljak</surname><given-names>L</given-names></name><etal/></person-group><article-title>Mice deficient in nuclear factor (NF)-<italic>&#x003ba;</italic>B/p52 present with defects in humoral responses, germinal center reactions, and splenic microarchitecture</article-title><source><italic>Journal of Experimental Medicine</italic></source><year>1998</year><volume>187</volume><issue>2</issue><fpage>147</fpage><lpage>159</lpage><pub-id pub-id-type="pmid">9432973</pub-id></citation></ref><ref id="B29"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Weih</surname><given-names>F</given-names></name><name><surname>Carrasco</surname><given-names>D</given-names></name><name><surname>Durham</surname><given-names>SK</given-names></name><etal/></person-group><article-title>Multiorgan inflammation and hematopoietic abnormalities in mice with a targeted disruption of RelB, a member of the NF-<italic>&#x003ba;</italic>B/Rel family</article-title><source><italic>Cell</italic></source><year>1995</year><volume>80</volume><issue>2</issue><fpage>331</fpage><lpage>340</lpage><pub-id pub-id-type="pmid">7834753</pub-id></citation></ref><ref id="B30"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pikarsky</surname><given-names>E</given-names></name><name><surname>Porat</surname><given-names>RM</given-names></name><name><surname>Stein</surname><given-names>I</given-names></name><etal/></person-group><article-title>NF-<italic>&#x003ba;</italic>B functions as a tumour promoter in inflammation-associated cancer</article-title><source><italic>Nature</italic></source><year>2004</year><volume>431</volume><issue>7007</issue><fpage>461</fpage><lpage>466</lpage><pub-id pub-id-type="pmid">15329734</pub-id></citation></ref><ref id="B31"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sakurai</surname><given-names>T</given-names></name><name><surname>Maeda</surname><given-names>S</given-names></name><name><surname>Chang</surname><given-names>L</given-names></name><name><surname>Karin</surname><given-names>M</given-names></name></person-group><article-title>Loss of hepatic NF-<italic>&#x003ba;</italic>B activity enhances chemical hepatocarcinogenesis through sustained c-Jun N-terminal kinase 1 activation</article-title><source><italic>Proceedings of the National Academy of Sciences of the United States of America</italic></source><year>2006</year><volume>103</volume><issue>28</issue><fpage>10544</fpage><lpage>10551</lpage><pub-id pub-id-type="pmid">16807293</pub-id></citation></ref><ref id="B32"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Van Antwerp</surname><given-names>DJ</given-names></name><name><surname>Martin</surname><given-names>SJ</given-names></name><name><surname>Kafri</surname><given-names>T</given-names></name><name><surname>Green</surname><given-names>DR</given-names></name><name><surname>Verma</surname><given-names>IM</given-names></name></person-group><article-title>Suppression of TNF-<italic>&#x003b1;</italic>-induced apoptosis by NF-<italic>&#x003ba;</italic>B</article-title><source><italic>Science</italic></source><year>1996</year><volume>274</volume><issue>5288</issue><fpage>787</fpage><lpage>789</lpage><pub-id pub-id-type="pmid">8864120</pub-id></citation></ref><ref id="B33"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>C-Y</given-names></name><name><surname>Mayo</surname><given-names>MW</given-names></name><name><surname>Baldwin</surname><given-names>AS</given-names><suffix>Jr.</suffix></name></person-group><article-title>TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-<italic>&#x003ba;</italic>B</article-title><source><italic>Science</italic></source><year>1996</year><volume>274</volume><issue>5288</issue><fpage>784</fpage><lpage>787</lpage><pub-id pub-id-type="pmid">8864119</pub-id></citation></ref><ref id="B34"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Beg</surname><given-names>AA</given-names></name><name><surname>Baltimore</surname><given-names>D</given-names></name></person-group><article-title>An essential role for NF-<italic>&#x003ba;</italic>B in preventing TNF-<italic>&#x003b1;</italic>-induced cell death</article-title><source><italic>Science</italic></source><year>1996</year><volume>274</volume><issue>5288</issue><fpage>782</fpage><lpage>784</lpage><pub-id pub-id-type="pmid">8864118</pub-id></citation></ref><ref id="B35"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schoemaker</surname><given-names>MH</given-names></name><name><surname>Ros</surname><given-names>JE</given-names></name><name><surname>Homan</surname><given-names>M</given-names></name><etal/></person-group><article-title>Cytokine regulation of pro- and anti-apoptotic genes in rat hepatocytes: NF-<italic>&#x003ba;</italic>B-regulated inhibitor of apoptosis protein 2 (cIAP2) prevents apoptosis</article-title><source><italic>Journal of Hepatology</italic></source><year>2002</year><volume>36</volume><issue>6</issue><fpage>742</fpage><lpage>750</lpage><pub-id pub-id-type="pmid">12044523</pub-id></citation></ref><ref id="B36"><label>36</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Bialik</surname><given-names>S</given-names></name><name><surname>Jones</surname><given-names>BE</given-names></name><etal/></person-group><article-title>NF-<italic>&#x003ba;</italic>B inactivation converts a hepatocyte cell line TNF-<italic>&#x003b1;</italic> response from proliferation to apoptosis</article-title><source><italic>American Journal of Physiology</italic></source><year>1998</year><volume>275</volume><issue>4, part 1</issue><fpage>C1058</fpage><lpage>C1066</lpage><pub-id pub-id-type="pmid">9755059</pub-id></citation></ref><ref id="B37"><label>37</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>Z</given-names></name><name><surname>Lee</surname><given-names>EY</given-names></name><name><surname>Robertson</surname><given-names>LW</given-names></name><name><surname>Glauert</surname><given-names>HP</given-names></name><name><surname>Spear</surname><given-names>BT</given-names></name></person-group><article-title>Effect of 2,2&#x02032;,4,4&#x02032;,5,5&#x02032;-hexachlorobiphenyl (PCB-153) on hepatocyte proliferation and apoptosis in mice deficient in the p50 subunit of the transcription factor NF-<italic>&#x003ba;</italic>B</article-title><source><italic>Toxicological Sciences</italic></source><year>2004</year><volume>81</volume><issue>1</issue><fpage>35</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">15201435</pub-id></citation></ref><ref id="B38"><label>38</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tharappel</surname><given-names>JC</given-names></name><name><surname>Nalca</surname><given-names>A</given-names></name><name><surname>Owens</surname><given-names>AB</given-names></name><etal/></person-group><article-title>Cell proliferation and apoptosis are altered in mice deficient in the NF-<italic>&#x003ba;</italic>B p50 subunit after treatment with the peroxisome proliferator ciprofibrate</article-title><source><italic>Toxicological Sciences</italic></source><year>2003</year><volume>75</volume><issue>2</issue><fpage>300</fpage><lpage>308</lpage><pub-id pub-id-type="pmid">12883078</pub-id></citation></ref><ref id="B39"><label>39</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>DeAngelis</surname><given-names>RA</given-names></name><name><surname>Kovalovich</surname><given-names>K</given-names></name><name><surname>Cressman</surname><given-names>DE</given-names></name><name><surname>Taub</surname><given-names>R</given-names></name></person-group><article-title>Normal liver regeneration in p50/nuclear factor <italic>&#x003ba;</italic>B1 knockout mice</article-title><source><italic>Hepatology</italic></source><year>2001</year><volume>33</volume><issue>4</issue><fpage>915</fpage><lpage>924</lpage><pub-id pub-id-type="pmid">11283856</pub-id></citation></ref><ref id="B40"><label>40</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chaisson</surname><given-names>ML</given-names></name><name><surname>Brooling</surname><given-names>JT</given-names></name><name><surname>Ladiges</surname><given-names>W</given-names></name><name><surname>Tsai</surname><given-names>S</given-names></name><name><surname>Fausto</surname><given-names>N</given-names></name></person-group><article-title>Hepatocyte-specific inhibition of NF-<italic>&#x003ba;</italic>B leads to apoptosis after TNF treatment, but not after partial hepatectomy</article-title><source><italic>Journal of Clinical Investigation</italic></source><year>2002</year><volume>110</volume><issue>2</issue><fpage>193</fpage><lpage>202</lpage><pub-id pub-id-type="pmid">12122111</pub-id></citation></ref><ref id="B41"><label>41</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kato</surname><given-names>A</given-names></name><name><surname>Edwards</surname><given-names>MJ</given-names></name><name><surname>Lentsch</surname><given-names>AB</given-names></name></person-group><article-title>Gene deletion of NF-<italic>&#x003ba;</italic>B p50 does not alter the hepatic inflammatory response to ischemia/reperfusion</article-title><source><italic>Journal of Hepatology</italic></source><year>2002</year><volume>37</volume><issue>1</issue><fpage>48</fpage><lpage>55</lpage><pub-id pub-id-type="pmid">12076861</pub-id></citation></ref><ref id="B42"><label>42</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Horwitz</surname><given-names>BH</given-names></name><name><surname>Zelazowski</surname><given-names>P</given-names></name><name><surname>Shen</surname><given-names>Y</given-names></name><etal/></person-group><article-title>The p65 subunit of NF-<italic>&#x003ba;</italic>B is redundant with p50 during B cell proliferative responses, and is required for germline C<sub>H</sub> transcription and class switching to IgG3</article-title><source><italic>The Journal of Immunology</italic></source><year>1999</year><volume>162</volume><issue>4</issue><fpage>1941</fpage><lpage>1946</lpage><pub-id pub-id-type="pmid">9973462</pub-id></citation></ref><ref id="B43"><label>43</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Snapper</surname><given-names>CM</given-names></name><name><surname>Zelazowski</surname><given-names>P</given-names></name><name><surname>Rosas</surname><given-names>FR</given-names></name><etal/></person-group><article-title>B cells from p50/NF-<italic>&#x003ba;</italic>B knockout mice have selective defects in proliferation, differentiation, germ-line CH transcription, and Ig class switching</article-title><source><italic>The Journal of Immunology</italic></source><year>1996</year><volume>156</volume><issue>1</issue><fpage>183</fpage><lpage>191</lpage><pub-id pub-id-type="pmid">8598461</pub-id></citation></ref><ref id="B44"><label>44</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Snapper</surname><given-names>CM</given-names></name><name><surname>Rosas</surname><given-names>FR</given-names></name><name><surname>Zelazowski</surname><given-names>P</given-names></name><etal/></person-group><article-title>B cells lacking RelB are defective in proliferative responses, but undergo normal B cell maturation to Ig secretion and Ig class switching</article-title><source><italic>Journal of Experimental Medicine</italic></source><year>1996</year><volume>184</volume><issue>4</issue><fpage>1537</fpage><lpage>1541</lpage><pub-id pub-id-type="pmid">8879226</pub-id></citation></ref><ref id="B45"><label>45</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Leung</surname><given-names>LK</given-names></name><name><surname>Glauert</surname><given-names>HP</given-names></name><name><surname>Spear</surname><given-names>BT</given-names></name></person-group><article-title>Treatment of rats with the peroxisome proliferator ciprofibrate results in increased liver NF-<italic>&#x003ba;</italic>B activity</article-title><source><italic>Carcinogenesis</italic></source><year>1996</year><volume>17</volume><issue>11</issue><fpage>2305</fpage><lpage>2309</lpage><pub-id pub-id-type="pmid">8968042</pub-id></citation></ref><ref id="B46"><label>46</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Costa</surname><given-names>RH</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Tronche</surname><given-names>R</given-names></name><name><surname>Yaniv</surname><given-names>M</given-names></name></person-group><article-title>HNF3 protein family</article-title><source><italic>Liver Gene Expression</italic></source><year>1994</year><publisher-loc>New York, NY, USA</publisher-loc><publisher-name>R.G. Landes Company</publisher-name><fpage>183</fpage><lpage>205</lpage></citation></ref><ref id="B58"><label>47</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ohmura</surname><given-names>T</given-names></name><name><surname>Ledda-Columbano</surname><given-names>GM</given-names></name><name><surname>Piga</surname><given-names>R</given-names></name><etal/></person-group><article-title>Hepatocyte proliferation induced by a single dose of a peroxisome proliferator</article-title><source><italic>American Journal of Pathology</italic></source><year>1996</year><volume>148</volume><issue>3</issue><fpage>815</fpage><lpage>824</lpage><pub-id pub-id-type="pmid">8774136</pub-id></citation></ref><ref id="B59"><label>48</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Menegazzi</surname><given-names>M</given-names></name><name><surname>Carcereri-De Prati</surname><given-names>A</given-names></name><name><surname>Suzuki</surname><given-names>H</given-names></name><etal/></person-group><article-title>Liver cell proliferation induced by nafenopin and cyproterone acetate is not associated with increases in activation of transcription factors NF-<italic>&#x003ba;</italic>B and AP-1 or with expression of tumor necrosis factor <italic>&#x003b1;</italic></article-title><source><italic>Hepatology</italic></source><year>1997</year><volume>25</volume><issue>3</issue><fpage>585</fpage><lpage>592</lpage><pub-id pub-id-type="pmid">9049203</pub-id></citation></ref><ref id="B51"><label>49</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Espandiari</surname><given-names>P</given-names></name><name><surname>Ludewig</surname><given-names>G</given-names></name><name><surname>Glauert</surname><given-names>HP</given-names></name><name><surname>Robertson</surname><given-names>LW</given-names></name></person-group><article-title>Activation of hepatic NF-<italic>&#x003ba;</italic>B by the herbicide Dicamba (2-methoxy-3,6-dichlorobenzoic acid) in female and male rats</article-title><source><italic>Journal of Biochemical and Molecular Toxicology</italic></source><year>1998</year><volume>12</volume><issue>6</issue><fpage>339</fpage><lpage>344</lpage><pub-id pub-id-type="pmid">9736482</pub-id></citation></ref><ref id="B56"><label>50</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rusyn</surname><given-names>I</given-names></name><name><surname>Tsukamoto</surname><given-names>H</given-names></name><name><surname>Thurman</surname><given-names>RG</given-names></name></person-group><article-title>WY-14 643 rapidly activates nuclear factor <italic>&#x003ba;</italic>B in Kupffer cells before hepatocytes</article-title><source><italic>Carcinogenesis</italic></source><year>1998</year><volume>19</volume><issue>7</issue><fpage>1217</fpage><lpage>1222</lpage><pub-id pub-id-type="pmid">9683180</pub-id></citation></ref><ref id="B57"><label>51</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rusyn</surname><given-names>I</given-names></name><name><surname>Yamashina</surname><given-names>S</given-names></name><name><surname>Segal</surname><given-names>BH</given-names></name><etal/></person-group><article-title>Oxidants from nicotinamide adenine dinucleotide phosphate oxidase are involved in triggering cell proliferation in the liver due to peroxisome proliferators</article-title><source><italic>Cancer Research</italic></source><year>2000</year><volume>60</volume><issue>17</issue><fpage>4798</fpage><lpage>4803</lpage><pub-id pub-id-type="pmid">10987289</pub-id></citation></ref><ref id="B53"><label>52</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Delerive</surname><given-names>P</given-names></name><name><surname>Gervois</surname><given-names>P</given-names></name><name><surname>Fruchart</surname><given-names>J-C</given-names></name><name><surname>Staels</surname><given-names>B</given-names></name></person-group><article-title>Induction of I<italic>&#x003ba;</italic>B<italic>&#x003b1;</italic> expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferator-activated receptor-<italic>&#x003b1;</italic> activators</article-title><source><italic>The Journal of Biological Chemistry</italic></source><year>2000</year><volume>275</volume><issue>47</issue><fpage>36703</fpage><lpage>36707</lpage><pub-id pub-id-type="pmid">10980195</pub-id></citation></ref><ref id="B50"><label>53</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tharappel</surname><given-names>JC</given-names></name><name><surname>Cunningham</surname><given-names>ML</given-names></name><name><surname>Spear</surname><given-names>BT</given-names></name><name><surname>Glauert</surname><given-names>HP</given-names></name></person-group><article-title>Differential activation of hepatic NF-<italic>&#x003ba;</italic>B in rats and hamsters by the peroxisome proliferators Wy-14,643, gemfibrozil, and dibutyl phthalate</article-title><source><italic>Toxicological Sciences</italic></source><year>2001</year><volume>62</volume><issue>1</issue><fpage>20</fpage><lpage>27</lpage><pub-id pub-id-type="pmid">11399789</pub-id></citation></ref><ref id="B49"><label>54</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fischer</surname><given-names>JG</given-names></name><name><surname>Glauert</surname><given-names>HP</given-names></name><name><surname>Yin</surname><given-names>T</given-names></name><name><surname>Sweeney-Reeves</surname><given-names>ML</given-names></name><name><surname>Larmonier</surname><given-names>N</given-names></name><name><surname>Black</surname><given-names>MC</given-names></name></person-group><article-title>Moderate iron overload enhances lipid peroxidation in livers of rats, but does not affect NF-<italic>&#x003ba;</italic>B activation induced by the peroxisome proliferator, Wy-14,643</article-title><source><italic>The Journal of Nutrition</italic></source><year>2002</year><volume>132</volume><issue>9</issue><fpage>2525</fpage><lpage>2531</lpage><pub-id pub-id-type="pmid">12221204</pub-id></citation></ref><ref id="B54"><label>55</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nanji</surname><given-names>AA</given-names></name><name><surname>Dannenberg</surname><given-names>AJ</given-names></name><name><surname>Jokelainen</surname><given-names>K</given-names></name><name><surname>Bass</surname><given-names>NM</given-names></name></person-group><article-title>Alcoholic liver injury in the rat is associated with reduced expression of peroxisome proliferator-<italic>&#x003b1;</italic> (PPAR<italic>&#x003b1;</italic>)-regulated genes and is ameliorated by PPAR<italic>&#x003b1;</italic> activation</article-title><source><italic>Journal of Pharmacology and Experimental Therapeutics</italic></source><year>2004</year><volume>310</volume><issue>1</issue><fpage>417</fpage><lpage>424</lpage><pub-id pub-id-type="pmid">15016835</pub-id></citation></ref><ref id="B52"><label>56</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Woods</surname><given-names>CG</given-names></name><name><surname>Burns</surname><given-names>AM</given-names></name><name><surname>Bradford</surname><given-names>BU</given-names></name><etal/></person-group><article-title>WY-14,643-induced cell proliferation and oxidative stress in mouse liver are independent of NADPH oxidase</article-title><source><italic>Toxicological Sciences</italic></source><year>2007</year><volume>98</volume><issue>2</issue><fpage>366</fpage><lpage>374</lpage><pub-id pub-id-type="pmid">17483499</pub-id></citation></ref><ref id="B48"><label>57</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Calfee-Mason</surname><given-names>KG</given-names></name><name><surname>Lee</surname><given-names>EY</given-names></name><name><surname>Spear</surname><given-names>BT</given-names></name><name><surname>Glauert</surname><given-names>HP</given-names></name></person-group><article-title>Role of the p50 subunit of NF-<italic>&#x003ba;</italic>B in vitamin E-induced changes in mice treated with the peroxisome proliferator, ciprofibrate</article-title><source><italic>Food and Chemical Toxicology</italic></source><year>2008</year><volume>46</volume><issue>6</issue><fpage>2062</fpage><lpage>2073</lpage><pub-id pub-id-type="pmid">18336980</pub-id></citation></ref><ref id="B47"><label>58</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Glauert</surname><given-names>HP</given-names></name><name><surname>Spear</surname><given-names>BT</given-names></name></person-group><article-title>NF<italic>&#x003ba;</italic>B activity is increased by the peroxisome proliferator ciprofibrate in rats</article-title><source><italic>Proceedings of the American Association of Cancer Research</italic></source><year>1996</year><volume>37</volume><fpage>p. 160</fpage></citation></ref><ref id="B55"><label>59</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Neschen</surname><given-names>S</given-names></name><name><surname>Moore</surname><given-names>I</given-names></name><name><surname>Regittnig</surname><given-names>W</given-names></name><etal/></person-group><article-title>Contrasting effects of fish oil and safflower oil on hepatic peroxisomal and tissue lipid content</article-title><source><italic>American Journal of Physiology</italic></source><year>2002</year><volume>282</volume><issue>2</issue><fpage>E395</fpage><lpage>E401</lpage><pub-id pub-id-type="pmid">11788372</pub-id></citation></ref><ref id="B60"><label>60</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>West</surname><given-names>DA</given-names></name><name><surname>James</surname><given-names>NH</given-names></name><name><surname>Cosulich</surname><given-names>SC</given-names></name><etal/></person-group><article-title>Role for tumor necrosis factor <italic>&#x003b1;</italic> receptor 1 and interleukin-1 receptor in the suppression of mouse hepatocyte apoptosis by the peroxisome proliferator nafenopin</article-title><source><italic>Hepatology</italic></source><year>1999</year><volume>30</volume><issue>6</issue><fpage>1417</fpage><lpage>1424</lpage><pub-id pub-id-type="pmid">10573520</pub-id></citation></ref><ref id="B61"><label>61</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kleemann</surname><given-names>R</given-names></name><name><surname>Verschuren</surname><given-names>L</given-names></name><name><surname>de Rooij</surname><given-names>B-J</given-names></name><etal/></person-group><article-title>Evidence for anti-inflammatory activity of statins and PPAR<italic>&#x003b1;</italic> activators in human C-reactive protein transgenic mice in vivo and in cultured human hepatocytes in vitro</article-title><source><italic>Blood</italic></source><year>2004</year><volume>103</volume><issue>11</issue><fpage>4188</fpage><lpage>4194</lpage><pub-id pub-id-type="pmid">14976045</pub-id></citation></ref><ref id="B62"><label>62</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cosulich</surname><given-names>SC</given-names></name><name><surname>James</surname><given-names>NH</given-names></name><name><surname>Needham</surname><given-names>MRC</given-names></name><name><surname>Newham</surname><given-names>PP</given-names></name><name><surname>Bundell</surname><given-names>KR</given-names></name><name><surname>Roberts</surname><given-names>RA</given-names></name></person-group><article-title>A dominant negative form of IKK2 prevents suppression of apoptosis by the peroxisome proliferator nafenopin</article-title><source><italic>Carcinogenesis</italic></source><year>2000</year><volume>21</volume><issue>9</issue><fpage>1757</fpage><lpage>1760</lpage><pub-id pub-id-type="pmid">10964109</pub-id></citation></ref><ref id="B63"><label>63</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Glauert</surname><given-names>HP</given-names></name><name><surname>Eyigor</surname><given-names>A</given-names></name><name><surname>Tharappel</surname><given-names>JC</given-names></name><name><surname>Cooper</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>EY</given-names></name><name><surname>Spear</surname><given-names>BT</given-names></name></person-group><article-title>Inhibition of hepatocarcinogenesis by the deletion of the p50 subunit of NF-<italic>&#x003ba;</italic>B in mice administered the peroxisome proliferator Wy-14,643</article-title><source><italic>Toxicological Sciences</italic></source><year>2006</year><volume>90</volume><issue>2</issue><fpage>331</fpage><lpage>336</lpage><pub-id pub-id-type="pmid">16434500</pub-id></citation></ref><ref id="B64"><label>64</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Inoue</surname><given-names>I</given-names></name><name><surname>Itoh</surname><given-names>F</given-names></name><name><surname>Aoyagi</surname><given-names>S</given-names></name><etal/></person-group><article-title>Fibrate and statin synergistically increase the transcriptional activities of PPAR<italic>&#x003b1;</italic>/RXR<italic>&#x003b1;</italic> and decrease the transactivation of NF<italic>&#x003ba;</italic>B</article-title><source><italic>Biochemical and Biophysical Research Communications</italic></source><year>2002</year><volume>290</volume><issue>1</issue><fpage>131</fpage><lpage>139</lpage><pub-id pub-id-type="pmid">11779144</pub-id></citation></ref><ref id="B65"><label>65</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Delerive</surname><given-names>P</given-names></name><name><surname>De Bosscher</surname><given-names>K</given-names></name><name><surname>Besnard</surname><given-names>S</given-names></name><etal/></person-group><article-title>Peroxisome proliferator-activated receptor <italic>&#x003b1;</italic> negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-<italic>&#x003ba;</italic>B and AP-1</article-title><source><italic>The Journal of Biological Chemistry</italic></source><year>1999</year><volume>274</volume><issue>45</issue><fpage>32048</fpage><lpage>32054</lpage><pub-id pub-id-type="pmid">10542237</pub-id></citation></ref><ref id="B66"><label>66</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Marx</surname><given-names>N</given-names></name><name><surname>Sukhova</surname><given-names>GK</given-names></name><name><surname>Collins</surname><given-names>T</given-names></name><name><surname>Libby</surname><given-names>P</given-names></name><name><surname>Plutzky</surname><given-names>J</given-names></name></person-group><article-title>PPAR<italic>&#x003b1;</italic> activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells</article-title><source><italic>Circulation</italic></source><year>1999</year><volume>99</volume><issue>24</issue><fpage>3125</fpage><lpage>3131</lpage><pub-id pub-id-type="pmid">10377075</pub-id></citation></ref><ref id="B67"><label>67</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Staels</surname><given-names>B</given-names></name><name><surname>Koenig</surname><given-names>W</given-names></name><name><surname>Habib</surname><given-names>A</given-names></name><etal/></person-group><article-title>Activation of human aortic smooth-muscle cells is inhibited by PPAR<italic>&#x003b1;</italic> but not by PPAR<italic>&#x003b3;</italic> activators</article-title><source><italic>Nature</italic></source><year>1998</year><volume>393</volume><issue>6687</issue><fpage>790</fpage><lpage>793</lpage><pub-id pub-id-type="pmid">9655393</pub-id></citation></ref><ref id="B68"><label>68</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Poynter</surname><given-names>ME</given-names></name><name><surname>Daynes</surname><given-names>RA</given-names></name></person-group><article-title>Peroxisome proliferator-activated receptor <italic>&#x003b1;</italic> activation modulates cellular redox status, represses nuclear factor-<italic>&#x003ba;</italic>B signaling, and reduces inflammatory cytokine production in aging</article-title><source><italic>The Journal of Biological Chemistry</italic></source><year>1998</year><volume>273</volume><issue>49</issue><fpage>32833</fpage><lpage>32841</lpage><pub-id pub-id-type="pmid">9830030</pub-id></citation></ref><ref id="B69"><label>69</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wunderlich</surname><given-names>FT</given-names></name><name><surname>Luedde</surname><given-names>T</given-names></name><name><surname>Singer</surname><given-names>S</given-names></name><etal/></person-group><article-title>Hepatic NF-<italic>&#x003ba;</italic>B essential modulator deficiency prevents obesity-induced insulin resistance but synergizes with high-fat feeding in tumorigenesis</article-title><source><italic>Proceedings of the National Academy of Sciences of the United States of America</italic></source><year>2008</year><volume>105</volume><issue>4</issue><fpage>1297</fpage><lpage>1302</lpage><pub-id pub-id-type="pmid">18216263</pub-id></citation></ref><ref id="B70"><label>70</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Tharappel</surname><given-names>JC</given-names></name><name><surname>Cooper</surname><given-names>S</given-names></name><name><surname>Glenn</surname><given-names>M</given-names></name><name><surname>Glauert</surname><given-names>HP</given-names></name><name><surname>Spear</surname><given-names>BT</given-names></name></person-group><article-title>Expression of the hydrogen peroxide-generating enzyme fatty acyl CoA oxidase activates NF-<italic>&#x003ba;</italic>B</article-title><source><italic>DNA and Cell Biology</italic></source><year>2000</year><volume>19</volume><issue>2</issue><fpage>113</fpage><lpage>120</lpage><pub-id pub-id-type="pmid">10701777</pub-id></citation></ref><ref id="B71"><label>71</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lake</surname><given-names>BG</given-names></name><name><surname>Evans</surname><given-names>JG</given-names></name><name><surname>Cunninghame</surname><given-names>ME</given-names></name><name><surname>Price</surname><given-names>RJ</given-names></name></person-group><article-title>Comparison of the hepatic effects of nafenopin and WY-14,643 on peroxisome proliferation and cell replication in the rat and Syrian hamster</article-title><source><italic>Environmental Health Perspectives</italic></source><year>1993</year><volume>101</volume><issue>supplement 5</issue><fpage>241</fpage><lpage>247</lpage><pub-id pub-id-type="pmid">8013414</pub-id></citation></ref><ref id="B72"><label>72</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Durnford</surname><given-names>JM</given-names></name><name><surname>Hejtmancik</surname><given-names>MR</given-names></name><name><surname>Kurtz</surname><given-names>PJ</given-names></name><etal/></person-group><article-title>Peroxisomal enzyme activity and cell proliferation in rats, mice and hamsters exposed for 13-weeks to Wy-14,643 and gemfibrozil</article-title><source><italic>Toxicological Sciences</italic></source><year>1998</year><volume>42</volume><issue>supplement 1</issue><fpage>p. 11</fpage></citation></ref><ref id="B73"><label>73</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>O'Brien</surname><given-names>ML</given-names></name><name><surname>Cunningham</surname><given-names>ML</given-names></name><name><surname>Spear</surname><given-names>BT</given-names></name><name><surname>Glauert</surname><given-names>HP</given-names></name></person-group><article-title>Effects of peroxisome proliferators on glutathione and glutathione-related enzymes in rats and hamsters</article-title><source><italic>Toxicology and Applied Pharmacology</italic></source><year>2001</year><volume>171</volume><issue>1</issue><fpage>27</fpage><lpage>37</lpage><pub-id pub-id-type="pmid">11181109</pub-id></citation></ref><ref id="B74"><label>74</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>O'Brien</surname><given-names>ML</given-names></name><name><surname>Twaroski</surname><given-names>TP</given-names></name><name><surname>Cunningham</surname><given-names>ML</given-names></name><name><surname>Glauert</surname><given-names>HP</given-names></name><name><surname>Spear</surname><given-names>BT</given-names></name></person-group><article-title>Effects of peroxisome proliferators on antioxidant enzymes and antioxidant vitamins in rats and hamsters</article-title><source><italic>Toxicological Sciences</italic></source><year>2001</year><volume>60</volume><issue>2</issue><fpage>271</fpage><lpage>278</lpage><pub-id pub-id-type="pmid">11248139</pub-id></citation></ref></ref-list></back><floats-wrap><table-wrap id="tab1" position="float"><label>Table 1</label><caption><p>Effect of peroxisome proliferators on the activation of NF-<italic>&#x003ba;</italic>B in the liver in vivo.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Authors</th><th align="center" rowspan="1" colspan="1">Species</th><th align="left" rowspan="1" colspan="1">Agent</th><th align="left" rowspan="1" colspan="1">Dose</th><th align="left" rowspan="1" colspan="1">Time Points</th><th align="center" rowspan="1" colspan="1">Endpoint</th><th align="left" rowspan="1" colspan="1">Effect</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Li et al., 1996 [<xref ref-type="bibr" rid="B45">45</xref>]</td><td align="center" rowspan="1" colspan="1">Rats</td><td align="left" rowspan="1" colspan="1">Ciprofibrate</td><td align="left" rowspan="1" colspan="1">0.01% in diet</td><td align="left" rowspan="1" colspan="1">3, 6, 10 days</td><td align="center" rowspan="1" colspan="1">EMSA</td><td align="left" rowspan="1" colspan="1">Increased</td></tr><tr><td align="left" rowspan="1" colspan="1">Ohmura et al., 1996 [<xref ref-type="bibr" rid="B58">47</xref>]</td><td align="center" rowspan="1" colspan="1">Rats</td><td align="left" rowspan="1" colspan="1">BR-931</td><td align="left" rowspan="1" colspan="1">250 mg/kg single p.o. dose</td><td align="left" rowspan="1" colspan="1">0.5&#x02013;5 hr after single dose</td><td align="center" rowspan="1" colspan="1">EMSA</td><td align="left" rowspan="1" colspan="1">No effect</td></tr><tr><td align="left" rowspan="1" colspan="1">Menegazzi et al., 1997 [<xref ref-type="bibr" rid="B59">48</xref>]</td><td align="center" rowspan="1" colspan="1">Rats</td><td align="left" rowspan="1" colspan="1">Nafenopin</td><td align="left" rowspan="1" colspan="1">200 mg/kg single p.o. dose</td><td align="left" rowspan="1" colspan="1">0.5&#x02013;24 hr after single dose</td><td align="center" rowspan="1" colspan="1">EMSA</td><td align="left" rowspan="1" colspan="1">No effect</td></tr><tr><td align="left" rowspan="1" colspan="1">Nilakantan et al., 1998 [<xref ref-type="bibr" rid="B16">16</xref>]</td><td align="center" rowspan="1" colspan="1">Mice</td><td align="left" rowspan="1" colspan="1">Ciprofibrate</td><td align="left" rowspan="1" colspan="1">0.01% in diet</td><td align="left" rowspan="1" colspan="1">21 days</td><td align="center" rowspan="1" colspan="1">EMSA</td><td align="left" rowspan="1" colspan="1">Increased</td></tr><tr><td align="left" rowspan="1" colspan="1">Espandiari et al., 1998 [<xref ref-type="bibr" rid="B51">49</xref>]</td><td align="center" rowspan="1" colspan="1">Rats</td><td align="left" rowspan="1" colspan="1">Dicamba</td><td align="left" rowspan="1" colspan="1">1 or 3% in diet</td><td align="left" rowspan="1" colspan="1">7 days</td><td align="center" rowspan="1" colspan="1">EMSA</td><td align="left" rowspan="1" colspan="1">Increased</td></tr><tr><td align="left" rowspan="1" colspan="1">Rusyn et al., 1998 [<xref ref-type="bibr" rid="B56">50</xref>]</td><td align="center" rowspan="1" colspan="1">Rats</td><td align="left" rowspan="1" colspan="1">Wy-14,643</td><td align="left" rowspan="1" colspan="1">100 mg/kg single p.o. dose</td><td align="left" rowspan="1" colspan="1">1&#x02013;36 hr after single dose</td><td align="center" rowspan="1" colspan="1">EMSA</td><td align="left" rowspan="1" colspan="1">Increased at 2 and 8 hr; no change at 1, 24, and 36 hr</td></tr><tr><td align="left" rowspan="1" colspan="1">Rusyn et al., 2000 [<xref ref-type="bibr" rid="B57">51</xref>]</td><td align="center" rowspan="1" colspan="1">Rats</td><td align="left" rowspan="1" colspan="1">Wy-14,643</td><td align="left" rowspan="1" colspan="1">100 mg/kg single p.o. dose</td><td align="left" rowspan="1" colspan="1">2 hr after single dose</td><td align="center" rowspan="1" colspan="1">EMSA</td><td align="left" rowspan="1" colspan="1">Increased</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Mice</td><td align="left" rowspan="1" colspan="1">Wy-14,643</td><td align="left" rowspan="1" colspan="1">100 mg/kg single p.o. dose</td><td align="left" rowspan="1" colspan="1">2&#x02013;24 hr after single dose</td><td align="center" rowspan="1" colspan="1">EMSA</td><td align="left" rowspan="1" colspan="1">Increased</td></tr><tr><td align="left" rowspan="1" colspan="1">Delerive et al., 2000 [<xref ref-type="bibr" rid="B53">52</xref>]</td><td align="center" rowspan="1" colspan="1">Mice</td><td align="left" rowspan="1" colspan="1">Ciprofibrate</td><td align="left" rowspan="1" colspan="1">0.05% in diet</td><td align="left" rowspan="1" colspan="1">2 weeks</td><td align="center" rowspan="1" colspan="1">I<italic>&#x003ba;</italic>B<italic>&#x003b1;</italic> expression</td><td align="left" rowspan="1" colspan="1">Increased in wild-type but not PPAR<italic>&#x003b1;</italic>  &#x02212;/&#x02212; mice</td></tr><tr><td align="left" rowspan="1" colspan="1">Tharappel et al., 2001 [<xref ref-type="bibr" rid="B50">53</xref>]</td><td align="center" rowspan="1" colspan="1">Rats</td><td align="left" rowspan="1" colspan="1">Wy-14,643</td><td align="left" rowspan="1" colspan="1">0.05 or 0.005% in diet</td><td align="left" rowspan="1" colspan="1">6, 34, 90 days</td><td align="center" rowspan="1" colspan="1">EMSA</td><td align="left" rowspan="1" colspan="1">Increased</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Gemfibrozil</td><td align="left" rowspan="1" colspan="1">0.1 or 1.6% in diet</td><td align="left" rowspan="1" colspan="1">6, 34 days</td><td align="center" rowspan="1" colspan="1">EMSA</td><td align="left" rowspan="1" colspan="1">No effect</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Gemfibrozil</td><td align="left" rowspan="1" colspan="1">0.1 or 1.6% in diet</td><td align="left" rowspan="1" colspan="1">90 days</td><td align="center" rowspan="1" colspan="1">EMSA</td><td align="left" rowspan="1" colspan="1">Increased only at lower dose</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Dibutyl phthalate</td><td align="left" rowspan="1" colspan="1">0.5 or 2.0% in diet</td><td align="left" rowspan="1" colspan="1">6 days</td><td align="center" rowspan="1" colspan="1">EMSA</td><td align="left" rowspan="1" colspan="1">No effect</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Dibutyl phthalate</td><td align="left" rowspan="1" colspan="1">0.5 or 2.0% in diet</td><td align="left" rowspan="1" colspan="1">34, 90 days</td><td align="center" rowspan="1" colspan="1">EMSA</td><td align="left" rowspan="1" colspan="1">Increased</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Hamsters</td><td align="left" rowspan="1" colspan="1">Wy-14,643</td><td align="left" rowspan="1" colspan="1">0.05 or 0.005% in diet</td><td align="left" rowspan="1" colspan="1">6, 34, 90 days</td><td align="center" rowspan="1" colspan="1">EMSA</td><td align="left" rowspan="1" colspan="1">No effect</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Gemfibrozil</td><td align="left" rowspan="1" colspan="1">0.6 or 2.4% in diet</td><td align="left" rowspan="1" colspan="1">6, 34, 90 days</td><td align="center" rowspan="1" colspan="1">EMSA</td><td align="left" rowspan="1" colspan="1">No effect</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Dibutyl phthalate</td><td align="left" rowspan="1" colspan="1">0.5 or 2.0% in diet</td><td align="left" rowspan="1" colspan="1">6, 34, 90 days</td><td align="center" rowspan="1" colspan="1">EMSA</td><td align="left" rowspan="1" colspan="1">No effect</td></tr><tr><td align="left" rowspan="1" colspan="1">Fischer et al., 2002 [<xref ref-type="bibr" rid="B49">54</xref>]</td><td align="center" rowspan="1" colspan="1">Rats</td><td align="left" rowspan="1" colspan="1">Wy-14,643</td><td align="left" rowspan="1" colspan="1">0.1% in diet</td><td align="left" rowspan="1" colspan="1">10 days</td><td align="center" rowspan="1" colspan="1">EMSA</td><td align="left" rowspan="1" colspan="1">Increased</td></tr><tr><td align="left" rowspan="1" colspan="1">Tharappel et al., 2003 [<xref ref-type="bibr" rid="B38">38</xref>]</td><td align="center" rowspan="1" colspan="1">Mice</td><td align="left" rowspan="1" colspan="1">Ciprofibrate</td><td align="left" rowspan="1" colspan="1">0.01% in diet</td><td align="left" rowspan="1" colspan="1">10 days</td><td align="center" rowspan="1" colspan="1">EMSA</td><td align="left" rowspan="1" colspan="1">Increased</td></tr><tr><td align="left" rowspan="1" colspan="1">Calfee-Mason et al., 2004 [<xref ref-type="bibr" rid="B17">17</xref>]</td><td align="center" rowspan="1" colspan="1">Rats</td><td align="left" rowspan="1" colspan="1">Ciprofibrate</td><td align="left" rowspan="1" colspan="1">0.01% in diet</td><td align="left" rowspan="1" colspan="1">10 days</td><td align="center" rowspan="1" colspan="1">EMSA</td><td align="left" rowspan="1" colspan="1">Increased</td></tr><tr><td align="left" rowspan="1" colspan="1">Nanji et al., 2004 [<xref ref-type="bibr" rid="B54">55</xref>]</td><td align="center" rowspan="1" colspan="1">Rats</td><td align="left" rowspan="1" colspan="1">Clofibrate</td><td align="left" rowspan="1" colspan="1">100 mg/kg p.o. daily + fish oil</td><td align="left" rowspan="1" colspan="1">4 weeks</td><td align="center" rowspan="1" colspan="1">EMSA</td><td align="left" rowspan="1" colspan="1">No effect compared to fish oil alone; decreased ethanol-induced activation</td></tr><tr><td align="left" rowspan="1" colspan="1">Woods et al., 2007 [<xref ref-type="bibr" rid="B52">56</xref>]</td><td align="center" rowspan="1" colspan="1">Mice</td><td align="left" rowspan="1" colspan="1">Wy-14,643</td><td align="left" rowspan="1" colspan="1">0.1% in diet</td><td align="left" rowspan="1" colspan="1">1 week, 5 weeks, 5 months</td><td align="center" rowspan="1" colspan="1">EMSA</td><td align="left" rowspan="1" colspan="1">Increased in wild-type and NADPH oxidase-deficient mice; no effect in PPAR<italic>&#x003b1;</italic>-deficient mice</td></tr><tr><td align="left" rowspan="1" colspan="1">Calfee-Mason et al., 2008 [<xref ref-type="bibr" rid="B48">57</xref>]</td><td align="center" rowspan="1" colspan="1">Mice</td><td align="left" rowspan="1" colspan="1">Ciprofibrate</td><td align="left" rowspan="1" colspan="1">0.01% in diet</td><td align="left" rowspan="1" colspan="1">10 days</td><td align="center" rowspan="1" colspan="1">EMSA</td><td align="left" rowspan="1" colspan="1">Increased</td></tr></tbody></table></table-wrap></floats-wrap></article>